Skip to content
Teethgrinder – Lifestyle
Author:
Iterion Therapeutics
Iterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual Meeting
June 1, 2026